Company intelligence / Profile preview
Aldeyra Therapeutics
Lexington, Massachusetts, United States of Americaaldeyra.com ↗
- Ownership
- Public · ALDX
- Employees
- ~9
- Development stage
- Other
01
Overview
Aldeyra's lead product candidate reproxalap received a Complete Response Letter from the FDA in April 2025 for its New Drug Application for Dry Eye Disease. The company has completed enrollment in a new Phase 3 clinical trial with results expected in the second half of 2024, which is designed to enable potential resubmission of the NDA.
- Therapeutic areas
- GastroenterologyMetabolic DisordersOphthalmologyImmunologyDermatologyRare Diseases
- Modalities
- Small moleculesRASP modulators
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Financials
- Market cap
- $37.2M
- Total revenue
- $0
- Enterprise value
- $-40.5T
Beyond the preview
Go deeper on Aldeyra Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aldeyra Therapeutics.